Kevin J Frankowski

List of Publications by Year
in descending order

35	803	623734	501196
papers	citations	14 h-index	28 g-index

37	37	37	1229
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Divergent Electrochemical Carboamidation of Cyclic Amines. Journal of Organic Chemistry, 2022, 87, 1173-1193.	3.2	3
2	Advances in Sulfonamide Kappa Opioid Receptor Antagonists: Structural Refinement and Evaluation of CNS Clearance. ACS Chemical Neuroscience, 2022, 13, 1315-1332.	3.5	1
3	Structureâ€“Activity Relationships of a Negative Allosteric Modulator of the D3 Dopamine Receptor and Investigation of its Binding Site. FASEB Journal, 2022, 36, .	0.5	0
4	Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis. Journal of Medicinal Chemistry, 2022, 65, 8303-8331.	6.4	4
5	Development of pyrimidone D1 dopamine receptor positive allosteric modulators. Bioorganic and Medicinal Chemistry Letters, 2021, 31, 127696.	2.2	6
6	Structureâ€“activity relationship investigation of triazole-based kappa opioid receptor agonists. Medicinal Chemistry Research, 2021, 30, 1386-1396.	2.4	0
7	Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion. Nature Microbiology, 2020, 5, 1532-1541.	13.3	10
8	Discovery of sultam-containing small-molecule disruptors of the huntingtinâ€“calmodulin proteinâ€“protein interaction. Medicinal Chemistry Research, 2020, 29, 1187-1198.	2.4	2
9	Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D₃ Dopamine Receptor Agonist. Journal of Medicinal Chemistry, 2020, 63, 5526-5567.	6.4	15
10	Mutant Huntingtinâ€Calmodulin Interaction: Potential Therapeutic Target for Huntington's Disease. FASEB Journal, 2019, 33, 501.16.	0.5	0
11	Identification of a Novel Negative Allosteric Modulator of the D3 Dopamine Receptor. FASEB Journal, 2019, 33, 503.3.	0.5	0
12	Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 1067-1080.	2.3	9
13	Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Science Translational Medicine, 2018, 10, .	12.4	55
14	Identification of Positive Allosteric Modulators of the D₁ Dopamine Receptor That Act at Diverse Binding Sites. Molecular Pharmacology, 2018, 94, 1197-1209.	2.3	35
15	Structure-Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for Biased Signaling of the D2 Dopamine Receptor. Frontiers in Synaptic Neuroscience, 2018, 10, 2.	2.5	14
16	Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. Journal of Medicinal Chemistry, 2017, 60, 6364-6383.	6.4	12
17	Decahydrobenzoquinolin-5-one sigma receptor ligands: Divergent development of both sigma 1 and sigma 2 receptor selective examples. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5689-5694.	2.2	5
18	Autophagy activation by novel inducers prevents BECN2-mediated drug tolerance to cannabinoids. Autophagy, 2016, 12, 1460-1471.	9.1	12

#	Article	IF	Citations
19	Evaluating p97 Inhibitor Analogues for Potency against p97â€“p37 and p97â€“Npl4â€“Ufd1 Complexes. ChemMedChem, 2016, 11, 953-957.	3.2	13
20	Practical Electrochemical Anodic Oxidation of Polycyclic Lactams for Late Stage Functionalization. Angewandte Chemie - International Edition, 2015, 54, 10555-10558.	13.8	74
21	Benzothiazole and Pyrrolone Flavivirus Inhibitors Targeting the Viral Helicase. ACS Infectious Diseases, 2015, 1, 140-148.	3.8	44
22	Potency enhancement of the Îº-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif. Bioorganic and Medicinal Chemistry, 2015, 23, 3948-3956.	3.0	7
23	Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPÎ³S binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting. Neuropharmacology, 2015, 99, 131-141.	4.1	24
24	Structureâ€“Activity Relationship Studies of Functionally Selective Kappa Opioid Receptor Agonists that Modulate ERK 1/2 Phosphorylation While Preserving G Protein Over Î²Arrestin2 Signaling Bias. ACS Chemical Neuroscience, 2015, 6, 1411-1419.	3.5	48
25	Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy. ACS Chemical Biology, 2015, 10, 1887-1896.	3.4	10
26	Investigation of the role of Î²arrestin2 in kappa opioid receptor modulation in a mouse model of pruritus. Neuropharmacology, 2015, 99, 600-609.	4.1	38
27	Development of Functionally Selective, Small Molecule Agonists at Kappa Opioid Receptors. Journal of Biological Chemistry, 2013, 288, 36703-36716.	3.4	123
28	Development of functionally selective agonists at the kappa opioid receptor (KOR). FASEB Journal, 2013, 27, lb551.	0.5	0
29	Development of biased agonists at the kappa opioid receptor.. FASEB Journal, 2013, 27, .	0.5	2
30	Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. ACS Chemical Neuroscience, 2012, 3, 221-236.	3.5	42
31	Synthesis and receptor profiling ofStemonaalkaloid analogues reveal a potent class of sigma ligands. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6727-6732.	7.1	30
32	N-Alkyl-octahydroisoquinolin-1-one-8-carboxamides: Selective and Nonbasic Îº-Opioid Receptor Ligands. ACS Medicinal Chemistry Letters, 2010, 1, 189-193.	2.8	22
33	Syntheses of the Stemona Alkaloids (Â±)-Stenine, (Â±)-Neostenine, and (Â±)-13-Epineostenine Using a Stereodivergent Dielsâ€“Alder/Azido-Schmidt Reaction. Journal of the American Chemical Society, 2008, 130, 6018-6024.	13.7	103
34	Explorations of Stemona Alkaloid-Inspired Analogues: Skeletal Modification and Functional Group Diversification. ACS Combinatorial Science, 2008, 10, 721-725.	3.3	20
35	Small-Molecule Disruptors of Mutant Huntingtinâ€“Calmodulin Proteinâ€“Protein Interaction Attenuate Deleterious Effects of Mutant Huntingtin. ACS Chemical Neuroscience, 0, , .	3.5	3